New perspectives of treatment with fesoterodine fumarate in patients with overactive bladder

García-Baquero, Rodrigo; Madurga, Blanca; García, M.V.; Fernández, M; Rosety, J.M.; Álvarez-Ossorio, J.L.

doi:10.1016/j.acuroe.2012.05.016

Cited by 8 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The usual approach is to start off at the lowest available dose and escalate to a higher dose when needed [7]. Some physicians, however, prefer to start patients on a high dose and de-escalate if bothersome AEs are noted [17] due to lack of efficacy is one of the most common reasons for non-compliance and discontinuation with OAB therapies [15] [16]. Furthermore, some patients need a more rapid symptom reduction, so starting on high dose could be justified in cases of severe OAB [9], previous treatment failure [17] or when OAB symptoms have a significant impact on the patient's psychosocial environment [31].…”

Section: Discussionmentioning

confidence: 99%

“…The perception of lack of efficacy is one of the most common reasons for non-compliance and discontinuation of OAB therapies [15] [16]. Some physicians prefer to start patients on a high dose and de-escalate if bothersome adverse events are noted [17] in order to prevent discontinuation or loss of confidence in the treatment. In observational and flexible-dose studies approximately 50% -63% of the subjects opted for dose escalation [6] [18].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dose Pattern Evolution and Therapeutic Benefit in Patients on Solifenacin or Fesoterodine Treatment in Daily Clinical Practice

García-Mediero¹,

Sánchez-Ballester²,

Arumí³

2016

OJU

View full text Add to dashboard Cite

Aim: To explore in daily clinical practice the evolution in time of the fesoterodine and solifenacin dose pattern and assess the therapeutic benefit provided by the highest dose of these anti-muscarinics. Patients and Methods: This was a post-hoc analysis of data from an observational, crosssectional, retrospective and multicenter study. Adult patients diagnosed with over active bladder (OAB) who initiated fesoterodine or solifenacin treatment were included. Data on the prescribed treatment and dose, change of dose, reasons for switching and treatment benefit were recorded. Results: A total of 828 subjects were analyzed (262 receiving solifenacin and 566 fesoterodine). Most subjects were women with a mean time since diagnosis of more than one year and aged around 60 years old. The majority of patients initiated the OAB treatment with the lowest available dose (64% fesoterodine vs. 77% solifenacin). At the follow-up visit 54% of the fesoterodine group and 66% of the solifenacin opted for dose escalation. At the study visit, 70.1% fesoterodine vs. 43.3% solifenacin remained on the highest dose. A significantly greater proportion of subjects receiving fesoterodine 8 mg, reported higher improvement in terms of both patient-reportedtreatment benefit and clinical global impression compared with solifenacin 10 mg (p < 0.05). Conclusion: In routine clinical practice more than half of the patients opted for the higher dose and remained on it over time, suggesting a desire for greater efficacy. Fesoterodine 8 mg seems to provide greater benefits from the physician's and the patient's point of view compared with those provided by solifenacin 10 mg.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Dose Pattern Evolution and Therapeutic Benefit in Patients on Solifenacin or Fesoterodine Treatment in Daily Clinical Practice

García-Mediero¹,

Sánchez-Ballester²,

Arumí³

2016

OJU

View full text Add to dashboard Cite

show abstract

“…A second retrospective analysis of 158 women, for whom the previous antimuscarinic agent was ineffective or caused intolerable adverse events, evaluated the efficacy and safety of treatment with fesoterodine 8 mg for 3 months 71 . In patients who experienced an ineffective response with the previous antimuscarinic, fesoterodine 8 mg significantly improved urgency/UUI episodes, insufficient voiding, and OAB-q scores from baseline.…”

Section: Patients With Uuimentioning

confidence: 99%

Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review

Chapple

Oelke

Kaplan

et al. 2015

Current Medical Research and Opinion

View full text Add to dashboard Cite

Extensive evidence demonstrates the efficacy and safety of fesoterodine in relieving OAB symptoms, including urgency, urinary frequency, UUI, and nocturnal urgency, in patients with various clinical and demographic profiles. Trial results provide valuable information on fesoterodine treatment in specific patient populations, including both elderly and vulnerable elderly patients. Potential limitations of this review are that only English language articles in PubMed were searched and included.

show abstract

Beneficio terapéutico tras cambiar tolterodina por otros nuevos antimuscarínicos

Sánchez-Ballester¹,

Miranda²,

Rejas³

et al. 2014

Actas Urológicas Españolas

View full text Add to dashboard Cite

New perspectives of treatment with fesoterodine fumarate in patients with overactive bladder

Cited by 8 publications

References 39 publications

Dose Pattern Evolution and Therapeutic Benefit in Patients on Solifenacin or Fesoterodine Treatment in Daily Clinical Practice

Dose Pattern Evolution and Therapeutic Benefit in Patients on Solifenacin or Fesoterodine Treatment in Daily Clinical Practice

Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review

Beneficio terapéutico tras cambiar tolterodina por otros nuevos antimuscarínicos

Contact Info

Product

Resources

About